IQVIA unveils AI agents to transform drug research and clinical trials

USA – As artificial intelligence continues to shape the future of healthcare, global data science company IQVIA has taken a bold step by launching a new generation of AI-powered agents tailored for the life sciences industry.

These agents are designed to act like intelligent lab and research assistants, helping scientists work faster and more efficiently—from early drug discovery to full-scale clinical trials.

Announced during the NVIDIA GTC 2025 conference, the new technology comes from a collaboration between IQVIA and NVIDIA, first revealed in January.

The goal: to develop smarter, healthcare-specific AI systems that can understand medical language, process complex scientific data, and provide real-time insights during drug development and clinical research.

Built using NVIDIA’s powerful AI tools, these next-gen agents are more than just software—they’re active digital collaborators.

They can identify new drug targets, analyze trial data, summarize medical research, assess market potential, and even assist in communicating with healthcare professionals.

To ensure accuracy and safety, IQVIA used NVIDIA’s NeMo Customizer to fine-tune the agents using real-life healthcare data, and added NeMo Guardrails to make sure they behave safely in sensitive clinical environments.

The new system replaces IQVIA’s older, proprietary AI platform, offering stronger performance and a more flexible framework.

According to Bhavik Patel, President of IQVIA Commercial Solutions, this marks a “pivotal opportunity” to bring speed, accuracy, and smarter workflows to the world of medical research.

With drug development becoming more complex and time-sensitive, these AI agents are expected to save time and reduce human error, especially in managing large volumes of data.

Kimberly Powell, NVIDIA’s VP of Healthcare, said, “Every moment counts when planning clinical trials. By teaming up with IQVIA, we’re building AI agents that bring both speed and precision to life sciences.”

IQVIA is not alone in embracing this shift. NVIDIA also revealed similar partnerships with Novo Nordisk and Cure51, as more pharmaceutical and biotech companies explore AI’s potential to transform R&D.

However, as AI becomes more autonomous, it raises important questions about safety, oversight, and trust in clinical settings.